Antibody Information
General Information of This Antibody
Antibody ID | ANI0UTUMU |
|||||
---|---|---|---|---|---|---|
Antibody Name | Magacizumab |
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG4-kappa |
|||||
Antigen Name | Leucine-rich alpha-2-glycoprotein (LRG1) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LRG1-ADC 5 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.40% (Day 16) | Positive LRG1 expression (LRG1+++/++) | ||
Method Description |
Single-cell suspensions of 1 x106 B16F0 cells were injected subcutaneously into the lower back of Lrg1+/+ C57BL/6 mice in 100 mL PBS. Tumours were measured and therapy was initiated when tumour volumes reached 0.1 cm3. ADC was administered at a dose of 20 mg/kg treatments were administered by a single intraperitoneal injection every 7 days for 3 weeks.
Click to Show/Hide
|
||||
In Vivo Model | Melanoma CDX model | ||||
In Vitro Model | Melanoma | Melanoma cells | Homo sapiens |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.90 nM
|
Positive LRG1 expression (LRG1+++/++) | ||
Method Description |
5 x104 cells were seeded in 96-well plates and incubated at 37 overnight. Cells were thenexposed to a range of concentrations of the test compounds diluted in growth medium at pH 6.5 and at 37 as ADC 5 (0100 nM, 72 h). MTT reagent (12 mM) was then added to each well and cells were incubated for 4 h at 37 , followed by the addition of DMSO and further incubation at 37 1C for 1 h.
Click to Show/Hide
|
||||
In Vitro Model | Mouse melanoma | B16-F0 cells | CVCL_0604 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.